Alcohol Use Disorder

Categories: Genetic diseases, Mental diseases, Metabolic diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Alcohol Use Disorder

MalaCards integrated aliases for Alcohol Use Disorder:

Name: Alcohol Use Disorder 11 42 41 14 71 75
Alcohol Abuse 11 53 14 71
Alcoholism 42 43
Alcoholic Intoxication, Chronic 71
Alcohol-Related Disorders 71
Alcohol Dependence 42
Alcohol Addiction 42
Ethanol Abuse 11


External Ids:

Disease Ontology 11 DOID:1574
ICD9CM 34 305.0
MeSH 43 D000437
NCIt 49 C20701
SNOMED-CT 68 15167005
ICD10 31 F10.1 Z72.1
UMLS 71 C0001956 C0001973 C0085762 more

Summaries for Alcohol Use Disorder

MedlinePlus: 41 What is alcohol use disorder (AUD)? For most adults, moderate alcohol use is probably not harmful. However, about 18 million adult Americans have an alcohol use disorder (AUD). This means that their drinking causes distress and harm. AUD can range from mild to severe, depending on the symptoms. Severe AUD is sometimes called alcoholism or alcohol dependence. AUD is a disease that causes: Craving - a strong need to drink Loss of control - not being able to stop drinking once you've started Negative emotional state - feeling anxious and irritable when you are not drinking What is binge drinking? Binge drinking is drinking so much at once that your blood alcohol concentration (BAC) level is 0.08% or more. For a man, this usually happens after having 5 or more drinks within a few hours. For a woman, it is after about 4 or more drinks within a few hours. Not everyone who binge drinks has an AUD, but they are at higher risk for getting one. What are the dangers of too much alcohol? Too much alcohol is dangerous. Heavy drinking can increase the risk of certain cancers. It may lead to liver diseases, such as fatty liver disease and cirrhosis. It can also cause damage to the brain and other organs. Drinking during pregnancy can harm your baby. Alcohol also increases the risk of death from car crashes, injuries, homicide, and suicide. How do I know if I have an alcohol use disorder (AUD)? You may have an AUD if you can answer yes to two or more of these questions: In the past year, have you: Ended up drinking more or for a longer time than you had planned to? Wanted to cut down or stop drinking, or tried to, but couldn't? Spent a lot of your time drinking or recovering from drinking? Felt a strong need to drink? Found that drinking - or being sick from drinking - often interfered with your family life, job, or school? Kept drinking even though it was causing trouble with your family or friends? Given up or cut back on activities that you enjoyed just so you could drink? Gotten into dangerous situations while drinking or after drinking? Some examples are driving drunk and having unsafe sex. Kept drinking even though it was making you feel depressed or anxious? Or when it was adding to another health problem? Had to drink more and more to feel the effects of the alcohol? Had withdrawal symptoms when the alcohol was wearing off? They include trouble sleeping, shakiness, irritability, anxiety, depression, restlessness, nausea, and sweating. In severe cases, you could have a fever, seizures, or hallucinations. If you have any of these symptoms, your drinking may already be a cause for concern. The more symptoms you have, the more serious the problem is. What should I do if I think that I might have an alcohol use disorder (AUD)? If you think you might have an AUD, see your health care provider for an evaluation. Your provider can help make a treatment plan, prescribe medicines, and if needed, give you treatment referrals. NIH: National Institute on Alcohol Abuse and Alcoholism

MalaCards based summary: Alcohol Use Disorder, also known as alcohol abuse, is related to post-traumatic stress disorder and personality disorder, and has symptoms including hangover from any alcohol or other drugs substance and hangover from alcohol. An important gene associated with Alcohol Use Disorder is CYP2E1 (Cytochrome P450 Family 2 Subfamily E Member 1), and among its related pathways/superpathways are Metabolism and Metapathway biotransformation Phase I and II. The drugs Disulfiram and Varenicline have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and prefrontal cortex, and related phenotypes are homeostasis/metabolism and nervous system

MedlinePlus Genetics: 42 Alcohol use disorder is a diagnosis made when an individual has severe problems related to drinking alcohol. Alcohol use disorder can cause major health, social, and economic problems, and can endanger affected individuals and others through behaviors prompted by impaired decision-making and lowered inhibitions, such as aggression, unprotected sex, or driving while intoxicated.Alcohol use disorder is a broad diagnosis that encompasses several commonly used terms describing problems with drinking. It includes alcoholism, also called alcohol addiction, which is a long-lasting (chronic) condition characterized by a powerful, compulsive urge to drink alcohol and the inability to stop drinking after starting. In addition to alcoholism, alcohol use disorder includes alcohol abuse, which involves problem drinking without addiction.Habitual excessive use of alcohol changes the chemistry of the brain and leads to tolerance, which means that over time the amount of alcohol ingested needs to be increased to achieve the same effect. Long-term excessive use of alcohol may also produce dependence, which means that when people stop drinking, they have physical and psychological symptoms of withdrawal, such as sleep problems, irritability, jumpiness, shakiness, restlessness, headache, nausea, sweating, anxiety, and depression. In severe cases, agitation, fever, seizures, and hallucinations can occur; this pattern of severe withdrawal symptoms is called delirium tremens.The heavy drinking that often occurs in alcohol use disorder, and can also occur in short-term episodes called binge drinking, can lead to a life-threatening overdose known as alcohol poisoning. Alcohol poisoning occurs when a large quantity of alcohol consumed over a short time causes problems with breathing, heart rate, body temperature, and the gag reflex. Signs and symptoms can include vomiting, choking, confusion, slow or irregular breathing, pale or blue-tinged skin, seizures, a low body temperature, a toxic buildup of substances called ketones in the blood (alcoholic ketoacidosis), and passing out (unconsciousness). Coma, brain damage, and death can occur if alcohol poisoning is not treated immediately.Chronic heavy alcohol use can also cause long-term problems affecting many organs and systems of the body. These health problems include irreversible liver disease (cirrhosis), inflammation of the pancreas (pancreatitis), brain dysfunction (encephalopathy), nerve damage (neuropathy), high blood pressure (hypertension), stroke, weakening of the heart muscle (cardiomyopathy), irregular heartbeats (arrhythmia), and immune system problems. Long-term overuse of alcohol also increases the risk of certain cancers, including cancers of the mouth, throat, esophagus, liver, and breast. Alcohol use in pregnant women can cause birth defects and fetal alcohol syndrome, which can lead to lifelong physical and behavioral problems in the affected child.

Disease Ontology: 11 A substance abuse that involves the recurring use of alcoholic beverages despite negative consequences.

Related Diseases for Alcohol Use Disorder

Diseases in the Alcohol Use Disorder family:

Alcohol Sensitivity, Acute

Diseases related to Alcohol Use Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1008)
# Related Disease Score Top Affiliating Genes
1 post-traumatic stress disorder 31.9 SLC6A4 SLC6A3 H2AC18 DRD2 CREB1 COMT
2 personality disorder 31.6 SLC6A4 SLC6A3 DRD3 DRD2 COMT ALDH2
3 anxiety 31.6 SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 CREB1
4 major depressive disorder 31.6 SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 CREB1
5 alcohol dependence 31.6 TF SLC6A4 SLC6A3 OPRM1 H2AC18 GPT
6 liver disease 31.4 TF HFE GPT GGT1 CYP2E1 ALDH2
7 bipolar disorder 31.4 SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 CREB1
8 withdrawal disorder 31.4 SLC6A4 SLC6A3 OPRM1 DRD2
9 attention deficit-hyperactivity disorder 31.3 SLC6A4 SLC6A3 OPRM1 H2AC18 DRD3 DRD2
10 antisocial personality disorder 31.3 SLC6A4 SLC6A3 DRD2 COMT ALDH2
11 mood disorder 31.3 SLC6A4 SLC6A3 H2AC18 DRD3 DRD2 CREB1
12 conduct disorder 31.3 SLC6A4 SLC6A3 DRD2 COMT ALDH2
13 bulimia nervosa 31.2 SLC6A4 SLC6A3 DRD2 COMT
14 alexithymia 31.2 SLC6A4 H2AC18 DRD2 COMT
15 liver cirrhosis 31.2 TF HFE GPT GGT1 CYP2E1 ALDH2
16 borderline personality disorder 31.2 SLC6A4 SLC6A3 DRD2 COMT
17 generalized anxiety disorder 31.2 SLC6A4 H2AC18 DRD2 COMT
18 schizophrenia 31.1 SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 CREB1
19 eating disorder 31.1 SLC6A4 SLC6A3 OPRM1 H2AC18 DRD2 COMT
20 psychotic disorder 31.1 SLC6A4 SLC6A3 OPRM1 H2AC18 DRD3 DRD2
21 alcoholic hepatitis 31.1 GPT GGT1 CYP2E1 ALDH9A1 ALDH2 ADH1B
22 nutritional deficiency disease 31.1 TF H2AC18 CCR6
23 chronic pain 31.0 OPRM1 COMT
24 social phobia 31.0 SLC6A4 SLC6A3 DRD2 COMT
25 tobacco addiction 31.0 SLC6A4 SLC6A3 OPRM1 H2AC18 GGT1 DRD3
26 sleep disorder 30.9 SLC6A4 SLC6A3 H2AC18 COMT
27 bipolar i disorder 30.9 SLC6A4 DRD2 COMT
28 toxic encephalopathy 30.9 SLC6A3 H2AC18 CREB1 CCR6
29 dysthymic disorder 30.9 SLC6A4 SLC6A3 COMT
30 endogenous depression 30.9 SLC6A4 SLC6A3 H2AC18 DRD2 CREB1 COMT
31 pathological gambling 30.9 SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 COMT
32 obsessive-compulsive disorder 30.9 SLC6A4 SLC6A3 DRD3 DRD2 COMT
33 panic disorder 30.9 SLC6A4 SLC6A3 DRD3 DRD2 COMT
34 substance abuse 30.8 TF SLC6A4 SLC6A3 OPRM1 MIR199A1 H2AC18
35 disease of mental health 30.8 SLC6A4 SLC6A3 OPRM1 MIR199A1 H2AC18 DRD3
36 paranoid schizophrenia 30.7 SLC6A4 H2AC18 DRD3 DRD2 COMT
37 oppositional defiant disorder 30.7 SLC6A4 SLC6A3 DRD3 DRD2 COMT
38 fatty liver disease 30.7 HFE GPT GGT1 CYP2E1
39 alcoholic cardiomyopathy 30.7 CYP2E1 ALDH2 ADH1B
40 intermittent explosive disorder 30.7 SLC6A4 DRD2 COMT
41 polysubstance abuse 30.7 DRD3 DRD2 COMT
42 cannabis abuse 30.7 SLC6A4 DRD2 COMT
43 cocaine abuse 30.7 SLC6A4 SLC6A3 OPRM1 H2AC18 DRD3 DRD2
44 peptic ulcer disease 30.7 H2AC18 GPT CCR6
45 drug dependence 30.7 SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 COMT
46 pancreatitis 30.6 GGT1 CYP2E1 ALDH2 ADH1C ADH1B
47 gilles de la tourette syndrome 30.6 SLC6A4 SLC6A3 DRD3 DRD2 COMT
48 alcoholic pancreatitis 30.6 CYP2E1 ALDH2 ADH1C ADH1B
49 opiate dependence 30.6 SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 CREB1
50 siderosis 30.6 TF HFE GPT

Comorbidity relations with Alcohol Use Disorder via Phenotypic Disease Network (PDN): (show all 20)

Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Alcoholic Cardiomyopathy
Alcoholic Gastritis Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Alcoholic Neuropathy
Alcohol-Induced Mental Disorder Cocaine Abuse
Deficiency Anemia Familial Atrial Fibrillation
Fatty Liver Disease Hepatic Encephalopathy
Hypertension, Essential Major Depressive Disorder
Pancreatitis, Hereditary Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Alcohol Use Disorder:

Diseases related to Alcohol Use Disorder

Symptoms & Phenotypes for Alcohol Use Disorder

UMLS symptoms related to Alcohol Use Disorder:

hangover from any alcohol or other drugs substance; hangover from alcohol

MGI Mouse Phenotypes related to Alcohol Use Disorder:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.16 ABCB7 ADH1B ADH1C ALDH2 CCR6 COMT
2 nervous system MP:0003631 10.1 ABCB7 ALDH2 CCR6 COMT CREB1 DRD2
3 growth/size/body region MP:0005378 10 ABCB7 ADH1B ADH1C ALDH2 CREB1 CYP2E1
4 cardiovascular system MP:0005385 9.7 ABCB7 ALDH2 CCR6 COMT CREB1 CYP2E1
5 mortality/aging MP:0010768 9.5 ABCB7 ADH1B ADH1C ALDH2 CREB1 CYP2E1

Drugs & Therapeutics for Alcohol Use Disorder

Drugs for Alcohol Use Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 333)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Disulfiram Approved Phase 4 97-77-8 3117
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
Baclofen Approved Phase 4 1134-47-0 2284
Topiramate Approved Phase 4 97240-79-4 5284627
Atomoxetine Approved Phase 4 82248-59-7, 83015-26-3 54841
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Sodium oxybate Approved Phase 4 502-85-2 23663870
Dutasteride Approved, Investigational Phase 4 164656-23-9 6918296
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
Lorazepam Approved Phase 4 846-49-1 3958
Sertraline Approved Phase 4 79617-96-2 68617
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
Acetaminophen Approved Phase 4 103-90-2 1983
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
Levetiracetam Approved Phase 4 102767-28-2 441341 5284583
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Chlorzoxazone Approved Phase 4 95-25-0 2733
Ribavirin Approved Phase 4 36791-04-5 37542
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
Oxazepam Approved Phase 4 604-75-1 4616
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
Acamprosate Approved, Investigational Phase 4 77337-73-6, 77337-76-9 71158
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
Nalmefene Approved, Investigational, Withdrawn Phase 4 55096-26-9 4422 5284594
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Clozapine Approved Phase 4 5786-21-0 2818 135398737
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
Asparagine Approved, Investigational, Nutraceutical Phase 4 70-47-3 6267
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
Choline Approved, Nutraceutical Phase 4 62-49-7 305
Cysteine Approved, Nutraceutical Phase 4 52-90-4 594 5862
Dexetimide Withdrawn Phase 4 21888-98-2 30843
41 Vasoconstrictor Agents Phase 4
42 Nicotinic Agonists Phase 4
43 Cholinergic Agents Phase 4
44 Immunologic Factors Phase 4
45 GABA Agonists Phase 4
46 Hypoglycemic Agents Phase 4
47 Antiparkinson Agents Phase 4
48 Nootropic Agents Phase 4
49 Neurosteroids Phase 4
50 5-alpha Reductase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 1325)
# Name Status NCT ID Phase Drugs
1 Phone-based Safety Monitoring of the First Year of Baclofen Treatment for Alcohol Use Disorder: the BACLOPHONE Cohort Study Unknown status NCT02596763 Phase 4 Baclofen
2 Baclofen Bij de Behandeling Van Acute Alcoholontwenning Unknown status NCT03293017 Phase 4 Diazepam 10 MG;Baclofen 30mg;Baclofen 60mg
3 Prospective Assessment of Valproate on Ethanol Withdrawal Unknown status NCT03235531 Phase 4 Valproate;Lorazepam
4 Antabuse in Severe Alcoholism: an Open Controlled Study Unknown status NCT00431262 Phase 4 antabuse (disulfiram)
5 Topiramate for Hospitalized Patients With Alcoholism: a 12-Week Open-Label Study Unknown status NCT01135602 Phase 4 Topiramate
6 The Role of Pharmacotherapy in Prevention of Relapse in Alcohol Dependence Unknown status NCT00120601 Phase 4 Naltrexone;Acamprosate
7 The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Unknown status NCT03018236 Phase 4 Alcohol N-acetylcysteine;Alcohol Placebo;Cocaine N-acetylcysteine;Cocaine Placebo
8 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
9 Ondansetron for Bipolar Disorder and Alcohol Use Disorders Completed NCT02082678 Phase 4 Ondansetron;Placebo
10 Neurocognitive Mechanisms of Disulfiram Treatment of Alcohol Use Disorder Completed NCT02735577 Phase 4 Disulfiram
11 Feasibility of Emergency Department Initiated Extended-Release Naltrexone and Case Management Services for the Treatment of Alcohol Use Disorder Completed NCT04094584 Phase 4 Vivitrol (Extended Release Naltrexone)
12 Multinational, Multicentre, Double-blind, Placebo-controlled Evaluation of the Efficacy of GHB in the Long-term Maintenance of Abstinence in Alcoholic Patients After the Initial Weaning Phase, Stratified by Lesch's Taxonomy (GATE 2) Completed NCT04648423 Phase 4 Sodium Oxybate;Placebo
13 Oral v. Injection Naltrexone in Hospital: Comparative Effectiveness for Alcoholism Completed NCT02478489 Phase 4 Oral naltrexone (PO-NTX);Extended-release injectable naltrexone (XR-NTX)
14 Novel Interventions for Alcohol Dependent Frequent Emergency Department Users: Phase IV, Randomized, Open-label, Non-placebo-controlled Study of Extended-release Naltrexone and Care Management on Healthcare Use, Drinking, & Quality of Life Completed NCT02445339 Phase 4 XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
15 SSRI Treatment of Dual Diagnosis PTSD and Alcohol Dependence: A Test of the Serotonergic Hypothesis Completed NCT02504931 Phase 4 Sertraline;Placebo
16 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
17 Oral Naltrexone for Improved Medication Compliance Among HIV-infected Men With Alcohol Use Disorder Completed NCT01377168 Phase 4 oral naltrexone;Placebo pill
18 A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence Completed NCT00452543 Phase 4 acamprosate;escitalopram;Placebo
19 Naltrexone Treatment of Alcohol Abuse in Schizophrenia Completed NCT00145847 Phase 4 Naltrexone or Placebo
20 Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial Completed NCT00190957 Phase 4 Atomoxetine;placebo
21 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Alcohol Abuse/ Dependence. Completed NCT00223249 Phase 4 Quetiapine
22 Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Alcohol Use in Adolescents & Young Adults Completed NCT00550394 Phase 4 quetiapine and placebo;Quetiapine and Topiramate
23 URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence Completed NCT03302299 Phase 4 Isoniazid 300 Mg ORAL TABLET;Pyridoxine 25 Mg Oral Tablet
24 Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia Completed NCT00156715 Phase 4 Quetiapine
25 Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST) Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
26 Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy Completed NCT01087736 Phase 4 Topiramate
27 Zonisamide vs. Placebo in the Treatment of Alcohol Dependence Completed NCT00595556 Phase 4 zonisamide;Placebo
28 Prevention Services in Schools for Early Drug Abuse Risk Completed NCT00257088 Phase 4
29 Placebo Controlled Pilot Study of Dutasteride for the Reduction of Alcohol Use in Male Drinkers Completed NCT01262287 Phase 4 Dutasteride;Placebo
30 Smoking Cessation in a Drug Treatment Program: A Randomized Trial of Varenicline Versus Placebo. Completed NCT01286584 Phase 4 varenicline;placebo
31 Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake Completed NCT01342341 Phase 4 Parafon Forte
32 Dutasteride Treatment for the Reduction of Heavy Drinking Completed NCT01758523 Phase 4 Dutasteride;sugar pill
33 Field Study of Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4 nicotine replacement patch
34 Naltrexone Treatment for Alcoholism: Predicting Outcome Completed NCT00000438 Phase 4 naltrexone (Revia)
35 Non-Response to Naltrexone (NTX): Next Steps in Managing Alcoholism Completed NCT00115037 Phase 4 Naltrexone;placebo
36 Naltrexone and Cognitive-Behavioral Therapy for Patients With Alcoholism and Post-Traumatic Stress Disorder Completed NCT00006489 Phase 4 Naltrexone;Placebo
37 Comparison of Cognitive Behavioral Therapy and Motivational Enhancement Therapy Plus Naltrexone for Alcoholism Completed NCT00000456 Phase 4 naltrexone (Revia)
38 Genetic and Brain Mechanisms of Naltrexone?s Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Naltrexone 50 Mg;Placebo
39 Individually Adapted Therapy of Alcoholism: Clinical Studies Completed NCT00317031 Phase 4 Acamprosate or Naltrexone
40 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
41 Phase Four Double-Blind Randomized Comparative Study on Thestudy on the Efficacy of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism Completed NCT00368862 Phase 4 Ebixa (memantine hydrochloride);Cipralex (escitalopram)
42 Sertraline Pharmacotherapy for Alcoholism Subtypes Completed NCT00368550 Phase 4 Sertraline;Placebo
43 Nalmefene Maintenance Treatment of Alcoholism Completed NCT00000450 Phase 4 Naltrexone Tablet;Matched Placebo Tablet
44 A Randomized, Multicenter, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Aripiprazole in the Maintenance of Abstinence From Alcohol in Subjects With Alcoholism Completed NCT00082199 Phase 4 Aripiprazole;Placebo
45 Identifying Multiple Mechanisms of Change in Alcoholism Treatment Completed NCT01168960 Phase 4
46 Targeted Naltrexone for Problem Drinkers Completed NCT00369408 Phase 4 Naltrexone;placebo
47 Alcohol Detoxification in Primary Care Treatment (ADEPT) - a Feasibility Study of Conducting a Randomised Trial in Primary Care Comparing Two Pharmacological Regimens. Completed NCT00855699 Phase 4 Acamprosate
48 The Effectiveness of Benfotiamine in Reducing Abusive Drinking Among Family History Positive and Negative Alcoholics Completed NCT00680121 Phase 4 Benfotiamine;Placebo
49 Defining an Endopheneotype for Alcohol Treatment With Naltrexone Completed NCT00817089 Phase 4 Placebo Oral Tablet;Naltrexone
50 A Double-Blind Placebo-Controlled Trial of Prazosin for the Treatment of Alcohol Dependence Completed NCT00167687 Phase 4 prazosin

Search NIH Clinical Center for Alcohol Use Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Citalopram hydrobromide
Naltrexone hydrochloride
Ondansetron Hydrochloride

Cochrane evidence based reviews: alcoholism

Genetic Tests for Alcohol Use Disorder

Anatomical Context for Alcohol Use Disorder

Organs/tissues related to Alcohol Use Disorder:

MalaCards : Liver, Brain, Prefrontal Cortex, Heart, Pancreas, Breast, Cortex

Publications for Alcohol Use Disorder

Articles related to Alcohol Use Disorder:

(show top 50) (show all 55061)
# Title Authors PMID Year
Association between DRD2/ANKK1 TaqIA Allele Status and Striatal Dopamine D2/3 Receptor Availability in Alcohol Use Disorder. 62 41
36424756 2022
Cognitive Processing Therapy or Relapse Prevention for comorbid Posttraumatic Stress Disorder and Alcohol Use Disorder: A randomized clinical trial. 62 41
36445895 2022
Three-year trajectories of alcohol use among at-risk and among low-risk drinkers in a general population sample of adults: A latent class growth analysis of a brief intervention trial. 41
36466482 2022
A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. 53 62
20153935 2010
The opioid systems--panacea and nemesis. 53 62
20494127 2010
Validation of a headspace solid-phase microextraction-GC-MS/MS for the determination of ethyl glucuronide in hair according to forensic guidelines. 53 62
20061100 2010
Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer - a narrative review. 53 62
19943812 2010
Brief motivational interviewing for DWI recidivists who abuse alcohol and are not participating in DWI intervention: a randomized controlled trial. 53 62
19930236 2010
RNA interference against aldehyde dehydrogenase-2: development of tools for alcohol research. 53 62
19251111 2009
[Association of the functional serotonin transporter promoter polymorphism (5-HTTLPR) with externalizing and internalizing aggressivity and alcohol abuse]. 53 62
19331786 2008
[Acute and chronic alcohol abuse and work]. 53 62
19288791 2008
Effectiveness of the CAGE questionnaire, gamma-glutamyltransferase and mean corpuscular volume of red blood cells as markers for alcohol-related problems in the workplace. 53 62
18337017 2008
The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload. 53 62
18061976 2008
[The concentration of sialylated glycoproteins in the sera of alcohol dependent men]. 53 62
18293845 2007
Development and multicenter evaluation of the N latex CDT direct immunonephelometric assay for serum carbohydrate-deficient transferrin. 53 62
17412797 2007
Biomarkers in alcoholism. 53 62
17045579 2007
Obesity and the clinical use of serum GGT activity as a marker of heavy drinking. 53 62
17763184 2007
Ethnicity and gamma-glutamyltransferase in men and women with alcohol use disorders. 53 62
17098749 2007
Genetic and environmental influences on the development of alcoholism: resilience vs. risk. 53 62
17347351 2006
Argininosuccinate lyase deficiency (ASL) and carbohydrate-deficient transferrin (CDT): experience with four independent CDT analysis methods--misleading results given by the %CDT TIA assay. 53 62
16808909 2006
[Alcohol abuse as a risk factor for ARDS]. 53 62
17176845 2006
Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. 53 62
16945079 2006
[New and traditional laboratory markers of alcohol abuse in hospitalized alcohol dependent men]. 53 62
17037822 2006
Association of galanin haplotypes with alcoholism and anxiety in two ethnically distinct populations. 53 62
16314872 2006
[New methods for the determination of transferrin isoforms in the diagnostics of alcohol abuse]. 53 62
16489296 2006
gamma-Glutamyltransferase is a promising biomarker for cardiovascular risk. 53 62
16891060 2006
[Depression of serum esterase and lipoprotein lipase activities in acute and longitudinal actions of ethanol]. 53 62
16739925 2006
Differential susceptibility of transferrin glycoforms to chymotrypsin: a proteomics approach to the detection of carbohydrate-deficient transferrin. 53 62
16331960 2005
Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. 53 62
16385229 2005
Use of laboratory markers and the audit questionnaire by primary care physicians to detect alcohol abuse by patients. 53 62
16215269 2005
Cytochrome P450 2E1 high activity polymorphism in alcohol abuse and end-organ disease. 53 62
16425414 2005
Disturbances of electrolytes and blood chemistry in acute alcohol intoxication. 53 62
15773422 2005
Clinicopathologic features and outcome after liver resection for hepatocellular carcinoma in patients with concurrent versus previous chronic hepatitis B. 53 62
15772792 2005
[Assessment of the usefulness of combination of selected clinical and demographic parameters in prediction of the severity of liver fibrosis in patients with chronic hepatitis C]. 53 62
16190546 2005
Serum sialic acid and gamma-glutamyltransferase levels in alcohol-dependent individuals. 53 62
15639592 2004
Multicenter validation study of the %CDT TIA kit in alcohol abuse and alcohol dependence. 53 62
15365303 2004
[Iron overload disease: recent findings]. 53 62
15529941 2004
Genetic polymorphism in ethanol metabolism: acetaldehyde contribution to alcohol abuse and alcoholism. 53 62
15164086 2004
Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. 53 62
15084894 2004
Clinical features and risk factors of patients with fatty liver in Guangzhou area. 53 62
15040041 2004
Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. 53 62
15288384 2004
Polymorphisms of the dopamine D2 receptor, serotonin transporter, and GABA(A) receptor beta(3) subunit genes and alcoholism in Mexican-Americans. 53 62
15066703 2004
[Study on the relationship between smoking, alcohol intake and hyperlipidemia in fishermen]. 53 62
14761628 2003
Use of biomarkers for alcohol use disorders in clinical practice. 53 62
14984245 2003
Anxiety and alcohol abuse disorders: a common role for CREB and its target, the neuropeptide Y gene. 53 62
12967770 2003
Transcription profiling reveals mitochondrial, ubiquitin and signaling systems abnormalities in postmortem brains from subjects with a history of alcohol abuse or dependence. 53 62
12774316 2003
Recognition of alcohol and substance abuse. 53 62
12722853 2003
The effects of ethanol on the glycosylation of human transferrin. 53 62
12626412 2003
Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. 53 62
12737448 2003
Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. 53 62
11704927 2001

Variations for Alcohol Use Disorder

Expression for Alcohol Use Disorder

LifeMap Discovery
Genes differentially expressed in tissues of Alcohol Use Disorder patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 ADAMTS18 ADAM metallopeptidase with thrombospondin type 1 motif 18 Brain - 3.66 0.005
Search GEO for disease gene expression data for Alcohol Use Disorder.

Pathways for Alcohol Use Disorder

Pathways related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
11.23 CYP2E1 ALDH9A1 ALDH2
4 11.05 CYP2E1 ALDH2 ADH1C ADH1B
Show member pathways
Show member pathways
Show member pathways
8 10.75 COMT ALDH9A1 ADH1B
Show member pathways
10.61 CYP2E1 ADH1B
10 10.59 ADH1C ADH1B
11 10.41 CYP2E1 CREB1
Show member pathways

GO Terms for Alcohol Use Disorder

Cellular components related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.28 SLC6A4 SLC6A3 OPRM1 HFE DRD3 DRD2
2 plasma membrane GO:0005887 10.28 SLC6A4 SLC6A3 OPRM1 HFE DRD3 DRD2
3 HFE-transferrin receptor complex GO:1990712 9.62 TF HFE
4 presynaptic membrane GO:0042734 9.55 SLC6A4 SLC6A3 OPRM1 DRD2
5 obsolete integral component of presynaptic membrane GO:0099056 9.26 SLC6A4 SLC6A3 OPRM1 DRD2
6 obsolete integral component of postsynaptic membrane GO:0099055 8.92 SLC6A4 SLC6A3 OPRM1 DRD2

Biological processes related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 response to xenobiotic stimulus GO:0009410 10.06 CREB1 CYP2E1 DRD2 DRD3 SLC6A3 SLC6A4
2 iron ion homeostasis GO:0055072 10.04 ABCB7 HFE TF
3 positive regulation of multicellular organism growth GO:0040018 10 SLC6A3 DRD2 CREB1
4 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.91 DRD3 DRD2
5 adenohypophysis development GO:0021984 9.9 SLC6A3 DRD2
6 hyaloid vascular plexus regression GO:1990384 9.89 SLC6A3 DRD2
7 cellular response to iron ion GO:0071281 9.88 TF HFE
8 dopamine uptake involved in synaptic transmission GO:0051583 9.88 SLC6A3 DRD2
9 response to iron ion GO:0010039 9.88 SLC6A3 HFE DRD2
10 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.86 DRD3 DRD2
11 regulation of potassium ion transport GO:0043266 9.85 DRD3 DRD2
12 dopamine metabolic process GO:0042417 9.85 DRD3 DRD2 COMT
13 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.84 DRD3 DRD2
14 response to morphine GO:0043278 9.83 OPRM1 DRD3 DRD2
15 regulation of iron ion transport GO:0034756 9.81 HFE TF
16 response to histamine GO:0034776 9.8 DRD2 DRD3
17 acid secretion GO:0046717 9.78 DRD2 DRD3
18 regulation of locomotion involved in locomotory behavior GO:0090325 9.76 DRD3 DRD2
19 prepulse inhibition GO:0060134 9.73 SLC6A3 DRD3 DRD2
20 response to ethanol GO:0045471 9.7 SLC6A3 OPRM1 DRD3 DRD2 CYP2E1
21 small molecule metabolic process GO:0044281 9.61 ADH1C ADH1B
22 alcohol metabolic process GO:0006066 9.26 ALDH2 ADH1C ADH1B
23 response to cocaine GO:0042220 9.23 SLC6A3 OPRM1 DRD3 DRD2

Molecular functions related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity GO:0043878 9.62 ALDH9A1 ALDH2
2 dopamine binding GO:0035240 9.56 SLC6A3 DRD2
3 alcohol dehydrogenase activity, zinc-dependent GO:0004024 9.46 ADH1C ADH1B
4 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD3 DRD2
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.92 DRD3 DRD2

Sources for Alcohol Use Disorder

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....